ストックスクリーナーアプリを入手
8.96
3.23%
0.28
アフターアワーズ：
8.96
前日終値:
$8.68
開ける：
$8.69
24時間の取引高:
88,233
Relative Volume:
1.96
時価総額：
$175.00M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.11%
1か月 パフォーマンス:
+23.42%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$8.673
$9.38
1週間の範囲:
$8.35
$9.39
52週間の値動き範囲:
$5.51
$10.16
Actuate Therapeutics Inc Stock (ACTU) Company Profile
ACTU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ACTU | 8.96 | 175.00M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Actuate Therapeutics Inc (ACTU) 最新ニュース
FDA OKs Ninlotinib Tablets With No Mealtime Restrictions for CML - www.oncnursingnews.com/
FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma - www.oncnursingnews.com/
FDA grants rare disease status to Actuate's Ewing sarcoma drug By Investing.com - Investing.com Australia
FDA grants rare disease status to Actuate's Ewing sarcoma drug - Investing.com India
Actuate Therapeutics : FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - Marketscreener.com
Actuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - MarketWatch
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - The Manila Times
Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.8%Time to Sell? - MarketBeat
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development - The Manila Times
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - GlobeNewswire
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - GlobeNewswire Inc.
Global Secondary Myelofibrosis Therapeutics Market Poised to Reach USD 2.74 Million by 2033 with a 6 - PharmiWeb.com
Pancreatic Cancer Market Size is Set for Rapid Growth as - openPR
Lantern Pharma to Host & Participate in Two Public Webinars During October - Business Wire
IPO Roundup: zSpace, Actuate Therapeutics and more - MSN
Bone Metastasis in Solid Tumors Market Expected to Experience - openPR
Quarterly IPOs Climb Back Above $1bn - In Vivo
Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.5%Here's What Happened - MarketBeat
Pancreatic Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
Actuate Announces Scientific Reports Publication on - GlobeNewswire
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor - Yahoo Finance
Bone metastasis in Solid Tumor Market Size is Set for Rapid Growth - openPR
Achilles Therapeutics Announces Strategic Update - StockTitan
Cintas (NASDAQ:CTAS) PT Raised to $225.00 - Defense World
Cintas (NASDAQ:CTAS) PT Raised to $225.00 at Truist Financial - MarketBeat
Capricor rises as it expands deal with Nippon Shinyaku - The Pharma Letter
Capricor Therapeutics Secures Lucrative European Partnership - TipRanks
Capricor Therapeutics Signs Binding Term Sheet with Nippon - GlobeNewswire
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - StockTitan
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga
Actuate Announces Upcoming Presentation on Initial Data on - GlobeNewswire
Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma - OncLive
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Behind the Bell: Actuate Therapeutics - Nasdaq
Elraglusib Granted FDA Orphan Drug Status in Soft Tissue Sarcoma - AJMC.com Managed Markets Network
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas - GlobeNewswire
Actuate gains FDA orphan drug status for cancer treatment - Investing.com
Biopharma financings near $78B, almost double last year’s value - BioWorld Online
Elraglusib shows promise in Ewing sarcoma trial - Investing.com
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewswire
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Stock Quotes, Forecast and News Summary - Benzinga
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs - Scrip
Actuate Therapeutics’ $22,4 Million Initial Public Offering - Global Legal Chronicle
Actuate Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Actuate Therapeutics Rings the Opening Bell - Nasdaq
Wheeling Native Daniel Schmitt To Ring Wall Street Bell - Wheeling Intelligencer
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 - GlobeNewswire
Actuate Therapeutics appoints new accounting firm By Investing.com - Investing.com Australia
Actuate Therapeutics Inc (ACTU) 財務データ
Actuate Therapeutics Inc (ACTU) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):